From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013 Apr;25(2):261-7 Authors: Angell H, Galon J Abstract The inherent complexity of multifactorial diseases such as cancer renders the process of patient prognosis and prediction of response to therapy extremely difficult. Many markers, signatures, and methods have been described to evaluate the prognosis of cancer patients, yet very few translate into the clinic. Systems biology approaches have facilitated analysis of the complex interaction between tumors and the host-immune response, and allowed the definition of the immune contexture. Here we review the potential of the immune contexture, quantified by the Immunoscore, to provide a statistically strong parameter for prognosis. Finally we introduce the concept that the host-immune reaction could be the critical element in determining response to therapy. The effect on the immune response could be the underlying factor behind many of the predictive markers. PMID: 23579076 [PubMed - in process]
Notch signaling is a highly conserved intercellular pathway with tightly regulated and pleiotropic roles in normal tissue development and homeostasis. Dysregulated Notch signaling has also been implicated in human disease, including multiple forms of cancer, and represents an emerging therapeutic target. Successful development of such therapeutics requires a detailed understanding of potential on-target toxicities. Here, we identify autosomal dominant mutations of the canonical Notch ligand Jagged1 (or JAG1) as a cause of peripheral nerve disease in 2 unrelated families with the hereditary axonal neuropathy Charcot-Marie-T...
States with the highest rates of melanoma cases linked to ultraviolet radiation are spread across the United States on the East and West coasts, in Hawaii and in landlocked states, according to a study published Monday in the International Journal of Cancer.
Patches made from human placenta could prevent men becoming impotent following prostate cancer surgery. Incontinence and erectile dysfunction can occur in up to seven in ten men.
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News